AnnovisBio is a brand at the forefront of a new direction in treating Alzheimer's Disease, Parkinson's Disease, and other neurodegenerative disorders. With an understanding of how the brain works and how brain cells die, AnnovisBio is developing transformative therapies for these devastating diseases. Their lead compound, buntanetap, attacks neurodegeneration by reducing multiple neurotoxic proteins, improving axonal transport, and ultimately preventing nerve cell death.

Unlike other drugs that target a single toxic protein, buntanetap inhibits the synthesis of amyloid precursor protein (APP), Tau, and α-Synuclein, the major neurotoxic proteins responsible for Alzheimer's and Parkinson's. Backed by a team of experienced professionals, including founder Dr. Maria L.

Maccecchini, CEO and President, AnnovisBio is committed to developing better therapeutics that address the urgent medical needs associated with neurodegenerative diseases. Their focus on innovative solutions and effective management of projects and resources ensures a comprehensive approach to research and development. Through their groundbreaking work, AnnovisBio aims to provide hope and improved outcomes for patients and their families affected by these debilitating conditions